- Home
- ERAS vs HPP Comparison
ERAS vs HPP Comparison
Compare ERAS & HPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- HPP
- Stock Information
- Founded
- ERAS 2018
- HPP 2009
- Country
- ERAS United States
- HPP United States
- Employees
- ERAS N/A
- HPP N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- HPP Real Estate
- Sector
- ERAS Health Care
- HPP Finance
- Exchange
- ERAS Nasdaq
- HPP Nasdaq
- Market Cap
- ERAS 432.6M
- HPP 374.6M
- IPO Year
- ERAS 2021
- HPP 2010
- Fundamental
- Price
- ERAS $1.16
- HPP $2.29
- Analyst Decision
- ERAS Strong Buy
- HPP Hold
- Analyst Count
- ERAS 6
- HPP 10
- Target Price
- ERAS $4.83
- HPP $3.32
- AVG Volume (30 Days)
- ERAS 2.3M
- HPP 3.1M
- Earning Date
- ERAS 05-07-2025
- HPP 05-07-2025
- Dividend Yield
- ERAS N/A
- HPP 2.19%
- EPS Growth
- ERAS N/A
- HPP N/A
- EPS
- ERAS N/A
- HPP N/A
- Revenue
- ERAS N/A
- HPP $834,774,000.00
- Revenue This Year
- ERAS N/A
- HPP N/A
- Revenue Next Year
- ERAS N/A
- HPP $4.97
- P/E Ratio
- ERAS N/A
- HPP N/A
- Revenue Growth
- ERAS N/A
- HPP N/A
- 52 Week Low
- ERAS $1.01
- HPP $2.00
- 52 Week High
- ERAS $3.45
- HPP $6.29
- Technical
- Relative Strength Index (RSI)
- ERAS 41.47
- HPP 38.73
- Support Level
- ERAS $1.01
- HPP $2.10
- Resistance Level
- ERAS $1.29
- HPP $3.10
- Average True Range (ATR)
- ERAS 0.17
- HPP 0.24
- MACD
- ERAS 0.00
- HPP -0.03
- Stochastic Oscillator
- ERAS 31.25
- HPP 26.36
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.